03 de septiembre del 2025
The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.
On Aug. 11, 2025, Pfizer initiated a recall of Octagam® Immune Globulin Intravenous (Human) 10% Liquid Preparation due to the potential for damaged bottles during transport. Damage to the bottles may result in leakage, reduced dosing, glass particulate contamination, and physical injury to healthcare providers, posing serious risks such as infection (including sepsis) and embolic events. Octagam is indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) and dermatomyositis (DM) in adults. For full prescribing information, see here.
Última actualización: 03 de septiembre del 2025